IL1B and rheumatoid arthritis: We also demonstrated in vitro that the treatment of neutrophils from RA patients with tocilizumab and infliximab normalized the levels of key inflammatory mediators including VEGF-A, TNFα, IL1-ß, IL8, IL6R and STAT3 [32].